Cargando…
Immunotherapeutic approaches to ovarian cancer treatment
Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for ovarian cancer patients are inadequate. Immunotherapy offers a novel and promising therapeutic strategy for treating ovarian tumors. Following the de...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372273/ https://www.ncbi.nlm.nih.gov/pubmed/25806106 http://dx.doi.org/10.1186/s40425-015-0051-7 |
_version_ | 1782363150500233216 |
---|---|
author | Chester, Cariad Dorigo, Oliver Berek, Jonathan S Kohrt, Holbrook |
author_facet | Chester, Cariad Dorigo, Oliver Berek, Jonathan S Kohrt, Holbrook |
author_sort | Chester, Cariad |
collection | PubMed |
description | Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for ovarian cancer patients are inadequate. Immunotherapy offers a novel and promising therapeutic strategy for treating ovarian tumors. Following the demonstration of the immunogenicity of ovarian tumors, multiple immunotherapeutic modalities have been developed. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor-modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery. |
format | Online Article Text |
id | pubmed-4372273 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43722732015-03-25 Immunotherapeutic approaches to ovarian cancer treatment Chester, Cariad Dorigo, Oliver Berek, Jonathan S Kohrt, Holbrook J Immunother Cancer Review Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for ovarian cancer patients are inadequate. Immunotherapy offers a novel and promising therapeutic strategy for treating ovarian tumors. Following the demonstration of the immunogenicity of ovarian tumors, multiple immunotherapeutic modalities have been developed. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor-modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery. BioMed Central 2015-03-24 /pmc/articles/PMC4372273/ /pubmed/25806106 http://dx.doi.org/10.1186/s40425-015-0051-7 Text en © Kohrt et al; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Chester, Cariad Dorigo, Oliver Berek, Jonathan S Kohrt, Holbrook Immunotherapeutic approaches to ovarian cancer treatment |
title | Immunotherapeutic approaches to ovarian cancer treatment |
title_full | Immunotherapeutic approaches to ovarian cancer treatment |
title_fullStr | Immunotherapeutic approaches to ovarian cancer treatment |
title_full_unstemmed | Immunotherapeutic approaches to ovarian cancer treatment |
title_short | Immunotherapeutic approaches to ovarian cancer treatment |
title_sort | immunotherapeutic approaches to ovarian cancer treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372273/ https://www.ncbi.nlm.nih.gov/pubmed/25806106 http://dx.doi.org/10.1186/s40425-015-0051-7 |
work_keys_str_mv | AT chestercariad immunotherapeuticapproachestoovariancancertreatment AT dorigooliver immunotherapeuticapproachestoovariancancertreatment AT berekjonathans immunotherapeuticapproachestoovariancancertreatment AT kohrtholbrook immunotherapeuticapproachestoovariancancertreatment |